Literature DB >> 33158741

Disparities in precision medicine-Examining germline genetic counseling and testing patterns among men with prostate cancer.

Hala T Borno1, Anobel Y Odisho2, Christine M Gunn3, Magdalena Pankowska4, Jennifer R Rider5.   

Abstract

INTRODUCTION: This study sought to examine whether germline genetic counseling and testing were employed differentially among men with prostate cancer by race and/or ethnicity and other social factors.
METHODS: In this retrospective analysis, all patients with prostate cancer listed as a visit diagnosis during the study period (April 2011 to August 2020) were identified from electronic health records. Patient characteristics were collected along with genetic counselor visits and germline genetic testing results in electronic health records. Multivariable analyses were performed with the primary outcome defined as the receipt of a genetic counseling visit and receipt of genetic testing.
RESULTS: A total of 14,610 patients with a prostate cancer diagnosis code were identified. The majority of patients were White (72%), aged >=65 years (62.7%), English-speaking (95%), married (71.4%), and publicly insured (58.7%). A total of 667 patients completed an appointment with a genetic counselor. A total of 439 patients received germline genetic test result, of whom 403 (91.8%) had also completed an appointment with a genetic counselor. Patients that were 65 years or older (adjusted odds ratio 0.53, 95%CI 0.44-0.65) and non-English proficient (adjusted odds ratio 0.71, 95%CI 0.42-1.21) were less likely to receive genetic counseling. Receiving genetic counseling was the strongest independent predictor of receipt of genetic testing.
CONCLUSIONS: The results of the current study highlight that the role of social factors in contributing to disparities in genetic counseling and testing among men with prostate cancer. These results underscore the importance of developing novel strategies to tackle contributors of observed disparities including language, age, and insurance status.
Copyright © 2020 Elsevier Inc. All rights reserved.

Entities:  

Keywords:  Cancer disparities; Germline genetics; Prostate cancer

Mesh:

Year:  2020        PMID: 33158741      PMCID: PMC9208066          DOI: 10.1016/j.urolonc.2020.10.014

Source DB:  PubMed          Journal:  Urol Oncol        ISSN: 1078-1439            Impact factor:   2.954


  24 in total

Review 1.  Improving the health and health care of non-English-speaking patients.

Authors:  D A Taira
Journal:  J Gen Intern Med       Date:  1999-05       Impact factor: 5.128

2.  A legacy for the children--attitudes of older adults in the United Kingdom to genetic testing.

Authors:  Heather Skirton; Lorraine Q Frazier; Amy O Calvin; Marlene Z Cohen
Journal:  J Clin Nurs       Date:  2006-05       Impact factor: 3.036

3.  Role of Cost-Sharing Subsidies on the Initiation of and Adherence to Tyrosine Kinase Inhibitor Therapy by Medicare Beneficiaries With Chronic Myeloid Leukemia.

Authors:  Ellen K Ritchie; Annie Guerin; Johannes Wolff; George Joseph
Journal:  J Clin Oncol       Date:  2017-02-13       Impact factor: 44.544

Review 4.  Disparities in gynecologic cancer genetics evaluation.

Authors:  Emily M Hinchcliff; Erica M Bednar; Karen H Lu; J Alejandro Rauh-Hain
Journal:  Gynecol Oncol       Date:  2019-01-31       Impact factor: 5.482

5.  Cost sharing and hereditary cancer risk: predictors of willingness-to-pay for genetic testing.

Authors:  Jennifer M Matro; Karen J Ruth; Yu-Ning Wong; Katen C McCully; Christina M Rybak; Neal J Meropol; Michael J Hall
Journal:  J Genet Couns       Date:  2014-05-06       Impact factor: 2.537

6.  Cancer knowledge and disparities in the information age.

Authors:  K Viswanath; Nancy Breen; Helen Meissner; Richard P Moser; Bradford Hesse; Whitney Randolph Steele; William Rakowski
Journal:  J Health Commun       Date:  2006

7.  Effective communication in the era of precision medicine: A pilot intervention with low health literacy patients to improve genetic counseling communication.

Authors:  Galen Joseph; Robin Lee; Rena J Pasick; Claudia Guerra; Dean Schillinger; Sara Rubin
Journal:  Eur J Med Genet       Date:  2018-12-13       Impact factor: 2.708

8.  Ethnic disparities among men with prostate cancer undergoing germline testing.

Authors:  Daniel Hyuck-Min Kwon; Hala T Borno; Heather H Cheng; Alicia Yiran Zhou; Eric Jay Small
Journal:  Urol Oncol       Date:  2019-10-17       Impact factor: 3.498

9.  Mediation analysis allowing for exposure-mediator interactions and causal interpretation: theoretical assumptions and implementation with SAS and SPSS macros.

Authors:  Linda Valeri; Tyler J Vanderweele
Journal:  Psychol Methods       Date:  2013-02-04

10.  Inherited DNA-Repair Gene Mutations in Men with Metastatic Prostate Cancer.

Authors:  Colin C Pritchard; Joaquin Mateo; Michael F Walsh; Navonil De Sarkar; Wassim Abida; Himisha Beltran; Andrea Garofalo; Roman Gulati; Suzanne Carreira; Rosalind Eeles; Olivier Elemento; Mark A Rubin; Dan Robinson; Robert Lonigro; Maha Hussain; Arul Chinnaiyan; Jake Vinson; Julie Filipenko; Levi Garraway; Mary-Ellen Taplin; Saud AlDubayan; G Celine Han; Mallory Beightol; Colm Morrissey; Belinda Nghiem; Heather H Cheng; Bruce Montgomery; Tom Walsh; Silvia Casadei; Michael Berger; Liying Zhang; Ahmet Zehir; Joseph Vijai; Howard I Scher; Charles Sawyers; Nikolaus Schultz; Philip W Kantoff; David Solit; Mark Robson; Eliezer M Van Allen; Kenneth Offit; Johann de Bono; Peter S Nelson
Journal:  N Engl J Med       Date:  2016-07-06       Impact factor: 91.245

View more
  2 in total

1.  Recommendations for the implementation of genetic testing for metastatic prostate cancer patients in Canada.

Authors:  Shamini Selvarajah; Kasmintan A Schrader; Michael P Kolinsky; Ricardo A Rendon; Soufiane El Hallani; Neil E Fleshner; Sebastien J Hotte; Justin Lorentz; Karen Panabaker; Renée Perrier; Frédéric Pouliot; Alan Spatz; Stephen Yip; Kim N Chi
Journal:  Can Urol Assoc J       Date:  2022-10       Impact factor: 2.052

2.  Adopting Consensus Terms for Testing in Precision Medicine.

Authors:  Nikki A Martin; Joel E Tepper; Veda N Giri; Thomas E Stinchcombe; Heather H Cheng; Milind M Javle; Eric Q Konnick
Journal:  JCO Precis Oncol       Date:  2021-10-06
  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.